ECT2 and urogenital neoplasm: Thus, our novel findings lay the foundation to further elucidate the anti-proliferative effects of 1α,25(OH)2D3 in non-malignant prostate maintenance and prostate carcinogenesis by targeting potential survival PCa biomarkers, ANLN and ECT2.